Aventis Pasteur S.a.

Sanofi Pasteur Sa

Sanofi Pasteur Inc.

Michel Chevalier

Tino Krell

Alain Francon

Eric Calvosa

Virginie Fabre

Catherine Moste

Sandrine Cigarini

Nadege Moreno

Suryaprakash Sambhara

Robert Brasseur

Isabelle Legastelois

Régis Sodoyer

Regis Sodoyer

Raphaëlle Claude El Habib

Bernard Meignier

Laurent Thion

Florence Boudet

Benoit Charloteaux

Raphaelle El Habib

Rapha&euml;lle El Habib

R&egrave;gis Sodoyer

The invention relates to a vaccine composition comprising: a) inactivated whole virus, and b) a stabilizing excipient which comprises: 

Stabilizing excipient for inactivated whole virus vaccine

The invention relates to a flu virus hemagglutinin-specific monoclonal antibody which recognizes an antigenic structure present both on the H1 and H3 subtypes of the hemagglutinins of type A flu viruses and on the hemagglutinin of type B flu viruses. Within type B flu viruses, the antigenic structure is present on the hemagglutinins of type B flu viruses belonging to the B/Victoria group and/or to the B/Yagamata group.

Flu virus hemagglutinin specific monoclonal antibodies

The invention relates to a vaccine composition comprising:

The present invention relates to a method for inducing antibodies neutralizing HIV primary isolates in a mammal, comprising administration of a pharmaceutical composition comprising a polypeptide represented by the formula N-L-C, in which:

Methods for inducing HIV-neutralizing antibodies

The present invention thus provides a polypeptide capable of forming a structure corresponding to or mimicking the intermediate of gp41 as well as its use in a vaccine for treating or preventing HIV infections.

Polypeptide inducing antibodies neutralizing HIV

The present invention comprises novel polypeptide antigens that can be used for therapeutic and prophylactic immunization against HIV-related infections. The polypeptide of the invention mimics the intermediate state of gp41 and is capable of inducing antibodies which neutralize primary isolates of HIV. The invention also comprises compositions comprising the polypeptide and methods of using it.

GP41 antigen

The invention concerns a purified recombinant glycoprotein having the following properties: a) an adherence capacity to CD4; b) an affinity with a anti-gp120 antibody capable of neutralizing in vitro HIV cell infection; c) an affinity with an anti-gp41 antibody; d) a timeric form free from inter-chain disulphide bonds. The invention also concerns a vaccine comprising said purified glycoprotein and an adjuvant. The invention further concerns a method for obtaining said glycoprotein, which consists in expressing, by means of genetic recombining techniques, a glycoprotein corresponding to the properties a), b) and c) mentioned above; purifying it, and subjecting it to steps involving at least a reducing agent, an ionic detergent and/or a neutral detergent in conditions leading to a glycoprotein having said properties.

Trimer of HIV env gene expression product

Method and device for cell lysis in which a liquid mixture of bateria or eukaryoptic cells and of a lysing agent is produced continuously, and this mixture is caused to flow immediately in a steady stream inside a tubing ( ), the flow rate of this stream being adjusted as a function of the diameter and of the length of the tubing ( ) so as to obtain a substantially homegenous cell lysate at the outlet ( ) of the said tubing.

Method and device for cell lysis

The invention relates to a method for enhancing the specific immune response against an immunogenic compound which comprises administering the immunogenic compound together with a poxvirus recombinant and a vaccinal antigen, which is not a poxvirus. The immunological material may be any biological material useful as a vaccine e.g., a polypeptide characteristic of a pathogenic microorganism or associated with a tumoral disorder, a DNA plasmid encoding a peptide or a polypeptide characteristic of a pathogenic microorganism or a tumor-associated antigen, or an hapten coupled to a carrier molecule. The poxvirus may be a live, attenuated or inactivated virus or a recombinant virus. Recombinant virus may encode a heterologous polypeptide such as chemokines, cytokines or co-immunostimulatory molecules or an homologous polypeptide, which is immunologically cross reactive with the immunogenic polypeptide or peptide.

Growing community of inventors

Beaurepaire, France

Michel Chevalier